St Bartholomew's Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2009

  1. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2008

  1. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

    British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229

2007

  1. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial

    Blood, Vol. 110, Núm. 10, pp. 3557-3560

  2. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

    British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435

2006

  1. A practical update on the use of bortezomib in the management of multiple myeloma

    Oncologist, Vol. 11, Núm. 1, pp. 51-61

2005

  1. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498